-+ 0.00%
-+ 0.00%
-+ 0.00%

Rodman & Renshaw Downgrades Karyopharm Therapeutics to Neutral

Benzinga·11/02/2026 18:28:28
Listen to the news
Rodman & Renshaw analyst Michael King downgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Buy to Neutral.